
A NEXT-GENERATION RESEARCH UNIVERSITY
At Georgia State, innovation is central to everything we do. In research, that means removing barriers to collaboration. It means recruiting faculty who can accelerate problem-solving. And it means encouraging researchers to think big, push boundaries and disrupt the status quo.
Georgia State faculty earned $224.72 million in research funding in fiscal year 2023, the highest total in university history.
Georgia State is among the nation’s top 146 public and private universities in the Carnegie Foundation’s elite category of Highest Research Activity.
The National Science Foundation ranks Georgia State #118 out of 648 schools nationwide for research expenditures, landing it among the top 20% for the fifth year in a row.
Cross-Cutting Research, Life-Changing Impact

Expanding Knowledge
ONE OF THE NATION'S FASTEST-GROWING RESEARCH PORTFOLIOS
In the past decade, Georgia State has been distinguished by the tremendous expansion of its research program. From fiscal year 2010 to fiscal year 2020, research expenditures at Georgia State have shot up by 150 percent, making the university one of the fastest-growing research institutions in the nation.
``Georgia State scientists oversee a wide-ranging research portfolio that is generating new insights and new discoveries in human health.``
– Susan Shows, President, Georgia Research Alliance
Research News
Study: Links Between Bullying and Self-Confidence in Youth With Disabilities Are Complex
New research reveals how bullying experiences differ among students with developmental disabilities.
Computer Science Professor Awarded $2 Million to Support Prescribed Fires
Xiaolin Hu and his team of researchers plan to use grant funding to develop a set of tools to help landowners better plan controlled burns.
Georgia State University Research Funding Sets Record for Third Year in a Row
The university's research community has set a new funding record for the third year in a row, with $224.72 million in grants earned in fiscal year 2023.
Molnupiravir Administered at Human Effect Size-Equivalent Dose Blocks SARS-CoV-2 Transmission in Ferrets, Researchers Find
Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), provide equivalent therapeutic benefit in preventing severe COVID-19 in animal models, but only molnupiravir efficiently blocked SARS-CoV-2 transmission when administered at a human effect size-equivalent dose, according to a study led by researchers at Georgia State University’s Center for Translational Antiviral Research in collaboration with the Emory University Institute for Drug Development.
Partner With Us
The Office of Technology Transfer makes discoveries available for licensing to business, industry and trade partners.
Find Research Support
Georgia State University’s Research Services & Administration works to support world-class research across the institution.
Get the Latest News
Subscribe to our research magazine and monthly e-newsletter and see how we’re making discoveries #THESTATEWAY®
Contact Us
Timothy L. Denning
Vice President for Research and Economic Development
[email protected]
Amanda Dobbs
Associate Director for Research PR & Communications
[email protected]
Noelle Toumey Reetz
Communications Manager
[email protected]